RDM Healthcare Research Network

分布式制造(RDM)的定义是：改变制造业经济和组织结构的技术、系统和战略，特别是在区位和规模方面。规模较小的本地制造业(RDM)的潜力及其对英国GDP的贡献在2013年11月的EPSRC再分配制造研讨会上得到了明确的阐述。正如研讨会报告总结的那样，英国工业的成功实施带来了许多挑战和机遇。创建一系列网络来探索和定义这些问题，以及解决这些问题所需的研究议程，是将多学科社区的专业知识运用到未来连贯的研究计划中的及时方法。我们专注于医疗设备和疗法的制造，反映了英国医疗保健的社会经济重要性。NHS在英国的营业额约为1210亿GB，为大约6400万公民提供服务--技术和服务的微小进步可能会产生巨大影响。医疗保健技术是EPSRC挑战赛的主题。拟议的RDM in Healthcare Network(RHN)目标将支持EPSRC确定的所有四个战略优先事项(新的治疗和治疗技术；在护理点实时增强的预测和诊断；健康生命过程的技术；以及医疗技术的设计、制造和集成)。RDM可以通过以下方式改变医疗产品的交付方式，提高国家竞争力和公民福祉：a)通过终端定制或基于灵活中间产品的延迟制造来降低成本；b)即时交付，特别是易腐烂的医疗产品；c)通过在当地制造中心之间共享支持服务来减少运营管理费用；d)通过横向扩展而不是纵向扩展来分配生产来管理产能；e)通过建立小生产单元来应对需求增长而不是单一的大工厂，从而避免将高昂的前期资本成本置于风险之中。实现这些好处的关键挑战在于：技术需求必须满足适当的监管标准；必须建立新的培训模式，以保持远距离运营质量；必须处理社会和人际特征，以提高生活质量，将质量保证纳入业务结构；必须建立新的客户-供应商关系。Rihn的目标是探索这些挑战和激励措施，并将由一个来自制造、管理、人为因素和医疗技术的多学科团队领导，将社会科学和工程学所需的专业知识结合起来。该联盟在提供主要的国家网络和研究中心方面拥有经验，并将建立在该团队与行业、临床网络、NHS、监管机构、政策制定者、学者和最终用户建立的已建立的关系的基础上。RiHN的目标是制定医疗保健RDM的研究议程，通过研讨会和用户参与活动与相关的学术和用户社区接触，并通过在五个不同领域进行可行性研究：1.医疗设备；2.制药；3.先进治疗(细胞和组织)；4.牙科；5.诊断。通过这样做，Rihn打算为RDM在医疗保健中建立一个实践社区，勾勒出未来的研究方向，并将在白皮书中发布。RHN的产出还将通过一个网站、在相关国家和国际会议上的介绍、参加区域发展管理网络的其他活动和研究中心以及介绍可行性研究结果的特刊期刊(《业务管理杂志》)来传播。最终报告将以电子形式发送给所有感兴趣的各方，并在Rihn的网站上提供。

'Re-distributed manufacture' (RDM) is defined as: Technology, systems and strategies that change the economics and organisation of manufacturing, particularly with regard to location and scale. The potential for smaller-scale local manufacturing (RDM) and its contribution to UK GDP was made clear at the EPSRC Re-Distributed Manufacturing Workshop in November 2013. As the Workshop report concluded, successful implementation in UK industry presents many challenges and opportunities. The creation of a series of Networks to explore and define these issues, and the research agenda required to resolve them, is a timely approach to harnessing the expertise of a multidisciplinary community into a future coherent research initiative.Our focus on manufacture of healthcare devices and therapies reflects the socio-economic importance of healthcare within the UK. The NHS has a turnover of some £121bn in the UK and serves a population of around 64m citizens - marginal advances in technology and services can have large impacts. Healthcare technologies are an EPSRC Challenge theme. The proposed RDM in Healthcare Network's (RiHN) objectives will support all four of the strategic priorities identified by EPSRC (novel treatment and therapeutic technologies; enhanced prediction and diagnosis in real time at the point-of-care; technologies for a healthy life course; and design, manufacture and integration of healthcare technologies). RDM may change the delivery of healthcare products, enhancing national competitiveness and citizen well-being through: a) Cost reduction through terminal customisation or delayed manufacture based upon flexible intermediate products; b) Just-in-time delivery, particularly of perishable healthcare goods, c) Reduction of operational overheads by sharing support services between local manufacturing hubs, d) Management of capacity by distributing production through scale-out, rather than scale-up, e) Avoidance of placing high up-front capital cost at risk by building small production units in response to increase in demand instead of single large factories.There are key challenges to realising these benefits: Technical needs must meet the appropriate regulatory standard; new training patterns must be established to maintain operating quality from a distance; social and inter-personal features must be addressed to enhance quality of life, incorporating quality assurance into the business structures; new customer-supplier relationships must be forged. RiHN aims to explore these challenges and incentives and will be led by a multi-disciplinary team drawn from manufacturing, management, human factors and healthcare technologies, combining the expertise required from both the social sciences and engineering. The consortium has experience in delivery of major national networks and research centres and will build on the established relationships that the team have with industry, clinical networks, the NHS, regulatory bodies, policy-makers, academics and end users.RiHN aims to develop the research agenda for RDM in healthcare, engaging with relevant academic and user communities through workshops and user engagement events, and through conducting feasibility studies in five distinct areas: 1. Medical Devices; 2. Pharmaceuticals; 3. Advanced Therapeutics (cell and tissue); 4. Dentistry; 5. Diagnostics. In doing so, RiHN intends to establish a community of practice for RDM in Healthcare, outlining the future direction for research, which will be published in a white paper. The outputs of RiHN will also be disseminated through a website, presentations at relevant national and international conferences, participation at other RDM Network events and research centres and a Special Issue journal (Journal of Operations Management) presenting the findings of the feasibility studies. A final report will be produced, sent electronically to all interested parties, and made available on RiHN's website.